Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TERIPARATIDE vs EUTHROID-1
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.
Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.
Treatment of postmenopausal women with osteoporosis at high risk for fracture,Treatment of men with primary or hypogonadal osteoporosis at high risk for fracture,Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
Hypothyroidism, primary, secondary, or tertiary,Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
20 mcg subcutaneously once daily.
One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.
Terminal half-life approximately 1 hour following subcutaneous administration; clinical duration limited by rapid clearance, necessitating once-daily dosing.
Terminal elimination half-life: approximately 5-7 days for levothyroxine (T4) and 2-4 days for liothyronine (T3). Clinical context: Steady-state achieved in 6-8 weeks; half-life prolonged in hypothyroidism, shortened in hyperthyroidism.
Teriparatide is metabolized via non-specific proteolytic degradation in the liver and peripheral tissues. No specific cytochrome P450 enzymes are involved.
Levothyroxine is deiodinated to liothyronine in peripheral tissues via iodothyronine deiodinases (DIO1, DIO2). Liothyronine undergoes deiodination and conjugation (glucuronidation, sulfation) in liver.
Primarily hepatic metabolism via nonspecific proteolytic enzymes; no significant renal or biliary excretion; minimal unchanged drug in urine or feces.
Renal: ~20-40% as unchanged drug; biliary/fecal: ~40-60% as metabolites and conjugates; total clearance is primarily hepatic.
Approximately 40-50% bound to plasma proteins, primarily albumin.
>99% bound; T4 bound to thyroxine-binding globulin (TBG: ~70%), transthyretin (10-15%), and albumin (15-20%); T3 binds less avidly to TBG and albumin.
Approximately 0.2-0.3 L/kg, indicating distribution largely confined to extracellular fluid and bone.
Vd: approximately 0.1-0.2 L/kg for T4; 0.3-0.5 L/kg for T3; reflects distribution primarily into extracellular fluid and limited tissue penetration for T4, wider distribution for T3.
Subcutaneous: approximately 95% bioavailability.
Oral: 50-80% for T4 (absorption depends on formulation and food); T3 nearly completely absorbed (>90%).
No dose adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not recommended in severe renal impairment (Cr Cl ≤30 m L/min) due to lack of data.
No specific GFR-based dose adjustment required; however, in severe renal failure, monitor thyroid function closely as drug clearance may be altered.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C).
No specific Child-Pugh based dose adjustment; caution in severe hepatic impairment due to altered metabolism of thyroid hormones.
Not approved for use in pediatric patients; safety and efficacy not established.
Weight-based dosing for hypothyroidism: initial 12.5-25 mcg levothyroxine equivalent per day, adjusted based on TSH and free T4 levels. Not recommended for children due to fixed combination ratio.
No dose adjustment required; clinical studies included patients >65 years with no significant differences in efficacy or safety.
Start with lower dose (e.g., half tablet) and titrate slowly; monitor for cardiac side effects due to increased sensitivity to thyroid hormones.
Increased risk of osteosarcoma in animal studies. Avoid use in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior radiation therapy involving the skeleton, or bone metastases.
No black box warning.
Risk of osteosarcoma (see black box warning),Orthostatic hypotension may occur, especially with initial doses,Hypercalcemia may occur; monitor serum calcium,Use with caution in patients with active urolithiasis,May increase serum uric acid
Cardiovascular toxicity with overdosage; may exacerbate angina, arrhythmias, hypertension. Caution in patients with diabetes mellitus (may increase blood glucose) and adrenal insufficiency. Monitor thyroid function tests and adjust dose.
Paget's disease of bone,Unexplained elevations of alkaline phosphatase,Open epiphyses (pediatric patients),Prior radiation therapy involving the skeleton,Bone metastases or history of skeletal malignancies,Metabolic bone diseases other than osteoporosis,Pregnancy and lactation,Hypersensitivity to teriparatide or any component
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
No specific food interactions. However, ensure adequate dietary calcium and vitamin D intake (e.g., dairy products, green leafy vegetables, fortified foods) to support the anabolic effect. Avoid excessive sodium, protein, and caffeine, which may increase calcium excretion. Do not take calcium supplements within 2 hours of teriparatide injection if instructed to take them separately, though generally they can be taken together.
Avoid high-fiber foods, grapefruit juice, and soy products within 4 hours of taking Euthyroid-1 as they may interfere with absorption. Maintain consistent iodine intake; avoid drastic increases in cruciferous vegetables (e.g., broccoli, kale) without medical advice. Calcium-fortified foods and iron-rich foods should be separated by at least 4 hours.
Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal skeletal effects.
EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits, preterm delivery, and low birth weight. Levothyroxine itself is not teratogenic; the FDA pregnancy category is A. No increased risk of congenital malformations has been reported with therapeutic doses. In the first trimester, adequate maternal T4 is critical for fetal brain development. In the second and third trimesters, placental transfer of levothyroxine is minimal as fetal thyroid function matures. Untreated hyperthyroidism from over-replacement may increase risk of fetal tachycardia, growth restriction, and preterm birth.
No human data; teriparatide likely excreted in milk in low amounts. M/P ratio unknown. Recommend caution or avoid breastfeeding.
Levothyroxine is excreted into breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. The estimated daily infant dose through breast milk is less than 1% of the maternal dose, which is negligible. No adverse effects in infants have been reported. The American Academy of Pediatrics considers levothyroxine compatible with breastfeeding. Monitoring of infant thyroid function is not routinely required but may be considered if maternal dose is high.
No dose adjustment recommended based on pharmacokinetic changes; however, use only if potential benefit justifies risk.
Pregnancy increases total body water, plasma volume, and renal clearance, and alters thyroid-binding globulin synthesis, leading to increased levothyroxine requirements. Dose adjustments are often needed as early as 4-6 weeks gestation. Typically, the dose is increased by 30-50% from preconception baseline. For patients already on levothyroxine, increase dose by 2 additional tablets per week (e.g., 2 extra doses) or approximately 30% upon confirmation of pregnancy. Monitor TSH every 4-6 weeks and adjust to maintain TSH <2.5 m IU/L in the first trimester and <3.0 m IU/L in later trimesters. After delivery, reduce dose to prepregnancy level and check TSH 6 weeks postpartum.
Teriparatide is a recombinant human parathyroid hormone analog used for osteoporosis. It is the only anabolic agent that stimulates new bone formation. Administer as a subcutaneous injection in the thigh or abdomen. Rotate injection sites. Do not use in patients with Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or bone metastases. Maximum duration of therapy is 24 months over a patient's lifetime due to an increased risk of osteosarcoma in rats. Monitor serum calcium levels at baseline and periodically; may cause transient hypercalcemia 4-6 hours after dosing. Contraindicated in hypercalcemia, pregnancy, and lactation.
Euthyroid-1 contains levothyroxine (T4) and liothyronine (T3) in a fixed 4:1 ratio. Monitor TSH, free T4, and free T3 levels to avoid overtreatment, especially due to T3 component. Use with caution in elderly and patients with cardiovascular disease; start with lower doses. T3 has a shorter half-life (about 1 day) vs T4 (7 days); consider this when interpreting labs. Drug interactions: iron, calcium, antacids, and bile acid sequestrants may reduce absorption; separate by at least 4 hours.
Store teriparatide in the refrigerator at 2-8°C (36-46°F) and never freeze. Protect from light and do not use if the solution is cloudy, colored, or contains particles.,Inject once daily using the provided pen device. Administer at the same time each day, preferably in the morning, into the thigh or abdomen. Rotate injection sites to avoid lipodystrophy.,Sit or lie down during the first few doses if you experience dizziness or rapid heartbeat, as teriparatide may cause orthostatic hypotension. Stand up slowly.,Do not use teriparatide for more than 24 months total over your lifetime. Inform your doctor if you have Paget's disease, a history of radiation therapy, or bone cancer.,Contact your doctor if you have persistent nausea, vomiting, constipation, muscle weakness, or confusion, as these may be signs of hypercalcemia.,Take calcium and vitamin D supplements as recommended by your doctor, typically 1000 mg calcium and 800 IU vitamin D daily, to support bone formation.
Take exactly as prescribed at the same time each day, usually in the morning on an empty stomach with water.,Do not stop or change dose without consulting your doctor; symptoms may take weeks to improve.,Inform your doctor of all other medications and supplements you take, especially iron, calcium, and antacids.,Report symptoms of hyperthyroidism (rapid heart rate, chest pain, sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Store at room temperature away from moisture and heat; keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TERIPARATIDE vs EUTHROID-1, answered by our medical review team.
TERIPARATIDE is a Parathyroid Hormone Analog that works by Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.. EUTHROID-1 is a Thyroid Hormone Replacement that works by Euthroid-1 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones that replace endogenous thyroid hormone. T4 is converted to T3 in peripheral tissues, acting on thyroid hormone receptors to regulate gene transcription, metabolism, and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TERIPARATIDE and EUTHROID-1 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TERIPARATIDE is: 20 mcg subcutaneously once daily.. The standard adult dose of EUTHROID-1 is: One tablet orally once daily, typically in the morning on an empty stomach. Contains 100 mcg levothyroxine and 25 mcg liothyronine.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TERIPARATIDE and EUTHROID-1 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TERIPARATIDE is classified as Category A/B. Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal ske. EUTHROID-1 is classified as Category C. EUTHROID-1 (levothyroxine) is a thyroid hormone replacement. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, fetal neurodevelopmental deficits,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.